Predicting Pre-emptive Discussions of Biologic Treatment: Results from an Openness and Preference Survey of Inflammatory Bowel Disease Patients and Their Prescribers
Open Access
- 8 May 2017
- journal article
- research article
- Published by Springer Nature in Advances in Therapy
- Vol. 34 (6) , 1398-1410
Abstract
It is important to compare patient and provider discrepancies on stated openness to and preference for biologics as well as predictors associated with initial discussions on biologic use.Keywords
Funding Information
- Janssen Pharmaceutica
This publication has 23 references indexed in Scilit:
- Review article: explaining risks of inflammatory bowel disease therapy to patientsAlimentary Pharmacology & Therapeutics, 2010
- Physician Communication and Patient Adherence to TreatmentMedical Care, 2009
- Making therapeutic decisions in inflammatory bowel disease: the role of patientsCurrent Opinion in Gastroenterology, 2009
- Review article: what do patients with inflammatory bowel disease want for their clinical management?Alimentary Pharmacology & Therapeutics, 2008
- Toward The ‘Tipping Point’: Decision Aids And Informed Patient ChoiceHealth Affairs, 2007
- Evolving knowledge and therapy of inflammatory bowel diseaseNature Reviews Drug Discovery, 2006
- Shared decision-making in the medical encounter: What does it mean? (or it takes at least two to tango)Social Science & Medicine, 1997
- Validation of a combined comorbidity indexJournal of Clinical Epidemiology, 1994
- Adapting a clinical comorbidity index for use with ICD-9-CM administrative databasesJournal of Clinical Epidemiology, 1992
- A power primer.Psychological Bulletin, 1992